MétaCan
Menu
Back to cohort
Record W3194380886 · doi:10.51731/cjht.2021.133

Utilization Patterns of Disease-Modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis: Rationale for Improving the Harmonization of Coverage Criteria

2021· article· en· W3194380886 on OpenAlexaboutno aff
Mina Tadrous, Mirhad Lončar, Peter Dyrda

Bibliographic record

VenueCanadian Journal of Health Technologies · 2021
Typearticle
Languageen
FieldImmunology and Microbiology
TopicBiosimilars and Bioanalytical Methods
Canadian institutionsnot available
Fundersnot available
KeywordsMedicineAdalimumabInfliximabLeflunomideAntirheumatic drugsEtanerceptRheumatoid arthritisTocilizumabHydroxychloroquineSulfasalazineAntirheumatic AgentsInternal medicineDisease

Abstract

fetched live from OpenAlex

Utilization patterns of csDMARDs were highly comparable between drug plans overall (in decreasing order: methotrexate, hydroxychloroquine, sulfasalazine, leflunomide, and azathioprine). The proportion of csDMARDs were comparable (e.g., approximately 30% of csDMARD use for methotrexate), although differences in coverage criteria may have resulted in variances in the use of leflunomide. Differences in adjudication of coverage criteria may have resulted in a modest variance in the number of csDMARDs used prior to initiating bDMARDs (i.e., allowing for an “early escape” to bDMARDs for some jurisdictions such as Manitoba and the Atlantic provinces). The mean time to initiate bDMARD therapy (range of 664 to 792 days) revealed a divergence between jurisdictions into 2 groupings whereby Manitoba, Saskatchewan, and the Atlantic provinces drug plans (mean time of 664 to 681 days) saw the initiation of bDMARDs approximately 4 months faster versus other jurisdictions (British Columbia, Alberta, and Ontario, with a mean time of 748 to 792 days), possibly due to their coverage criteria not requiring 3 lines of csDMARDs therapy. Despite differences in the time to initiate bDMARDs, there was no notable difference in the persistence of bDMARDs 6 months after the initiation for any drug plan (61% to 76% range for patients 67 years of age and older). Utilization patterns of bDMARDs was highly comparable between drug plans (i.e., highest use with adalimumab, etanercept, and infliximab), although British Columbia and Manitoba were the only jurisdictions that saw decreasing costs per patient of bDMARDs over time, likely due to a higher uptake of biosimilars or other managed formulary strategies such as tiering.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Other design · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.982
Threshold uncertainty score0.206

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.061
GPT teacher head0.323
Teacher spread0.262 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designOther design
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueCanadian Journal of Health TechnologiesSame topicBiosimilars and Bioanalytical MethodsFrench-language works237,207